Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 10/20 | 0.41 |
| ▸ | CTSS | P25774 | 6/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27895527 | 1.00 | SMN1; SMN2 (0.58) | SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL6719127 | 0.88 | SMN1; SMN2 (0.56) | SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL6722519 | 0.88 | SMN1; SMN2 (0.56) | SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL6722516 | 0.88 | SMN1; SMN2 (0.56) | SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL28968951 | 0.87 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL4371611 | 0.87 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL28968948 | 0.87 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL15722121 | 0.87 | SMN1; SMN2 (0.67) | SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL15722123 | 0.87 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL701700 | 0.87 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-6038785-A | — | — | None | — | — | JP | disclosed |
| EP-2566334-B1 | CONTROLLED DRUG RELEASE FROM SOLID SUPPORTS | PROLYNX LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-2566335-B1 | CONTROLLED RELEASE OF ACTIVE COMPOUNDS FROM MACROMOLECULAR CONJUGATES | PROLYNX LLC (US) | 2016-06-29 | — | — | EP | disclosed |
| US-8946405-B2 | Controlled release from solid supports | PROLYNX LLC (US) | 2015-02-03 | — | — | US | disclosed |
| US-8754190-B2 | Controlled release from macromolecular conjugates | PROLYNX LLC (US) | 2014-06-17 | — | — | US | disclosed |
| US-8703907-B2 | Controlled drug release from dendrimers | PROLYNX LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20130123487-A1 | CONTROLLED RELEASE FROM SOLID SUPPORTS | PROLYNX LLC (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123461-A1 | CONTROLLED DRUG RELEASE FROM DENDRIMERS | PROLYNX LLC (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130116407-A1 | CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES | PROLYNX LLC | 2013-05-09 | — | — | US | disclosed |
| CN-103025165-A | Controlled release from macromolecular conjugates | PROLYNX LLC | 2013-04-03 | — | — | CN | disclosed |
| EP-2571496-A1 | CONTROLLED DRUG RELEASE FROM DENDRIMERS | Prolynx Llc (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-2566334-A1 | CONTROLLED DRUG RELEASE FROM SOLID SUPPORTS | Prolynx Llc (US) | 2013-03-13 | — | — | EP | disclosed |
| EP-2566335-A1 | CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES | Prolynx Llc (US) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011140376-A1 | CONTROLLED DRUG RELEASE FROM DENDRIMERS | PROLYNX LLC (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140392-A1 | CONTROLLED DRUG RELEASE FROM SOLID SUPPORTS | PROLYNX LLC (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140393-A1 | CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES | PROLYNX LLC (US) | 2011-11-10 | — | — | WO | disclosed |
| US-6829540-B1 | Data processing, drug screening using immobilized artificial membrane chromatographic substrates in high pressure liquid chromatographic systems using aqueous mobile phases | PURDUE RESEARCH FOUNDATION | 2004-12-07 | — | — | US | disclosed |
| EP-1015623-A1 | DRUG DISCOVERY USING MULTIPLE MEMBRANE MIMETIC AFFINITIES | PURDUE RESEARCH FOUNDATION (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999010522-A1 | DRUG DISCOVERY USING MULTIPLE MEMBRANE MIMETIC AFFINITIES | PURDUE RESEARCH FOUNDATION (US) | 1999-03-04 | — | — | WO | disclosed |
| JP-H0638785-A | BETA-GALACTOSIDASE-CATALYZED TRANSGLYCOSIDATION WITH UNPHYSIOLOGICAL GLYCOSYL DONOR | HOECHST AG | 1994-02-15 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123487-A1 | CONTROLLED RELEASE FROM SOLID SUPPORTS | SLC43A1, ABCB1, NAPA | SMN1; SMN2 1154/4885CYP1A2 2085/4885CYP2C9 542/4885 |
| US-20130123461-A1 | CONTROLLED DRUG RELEASE FROM DENDRIMERS | SLC43A1, SLC47A1, SLC47A2 | SMN1; SMN2 2124/4885CYP1A2 2393/4885CYP2C9 809/4885 |
| US-20130116407-A1 | CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES | ABCB1, ABCB11, GUSB | SMN1; SMN2 1698/4885CYP1A2 2001/4885CYP2C9 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.